Befotertinib
Befotertinib Basic information
- Product Name:
- Befotertinib
- Synonyms:
-
- N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide
- 2-Propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)-1H-indol-3-yl]-2-pyrimidinyl]amino]phenyl]-
- Befotertinib
- CPD0557
- lung,Epidermal growth factor receptor,D0316,D 0316,ErbB-1,Inhibitor,HER1,inhibit,cancer,EGFR,kinase,tyrosine,non-small,NSCLC
- Befotertinib, 10 mM in DMSO
- Befotertinib (D-0316)
- CAS:
- 1835667-63-4
- MF:
- C29H32F3N7O2
- MW:
- 567.61
- Mol File:
- 1835667-63-4.mol
More
Less
Befotertinib Chemical Properties
- Density
- 1.26±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : 62.5 mg/mL (110.11 mM; ultrasonic and warming and heat to 60°C)
- pka
- 12.68±0.70(Predicted)
- form
- Solid
- color
- Light yellow to yellow
More
Less
Befotertinib Usage And Synthesis
Uses
Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC)[1].
References
[1] Nagasaka M, et, al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16(5):740-763. DOI:10.1016/j.jtho.2020.11.028
BefotertinibSupplier
BOC Sciences
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
Shanghai Lollane Biological Technology Co.,Ltd.
- Tel
- 021-52996696，15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
Kaixin Chemical (Hong Kong) Limited
- Tel
- 010-88886666-01 13112345678
- loyson@tcypharm.com